These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1822828)

  • 1. Cost-effectiveness of hormone replacement therapy after the menopause.
    Tosteson AN; Weinstein MC
    Baillieres Clin Obstet Gynaecol; 1991 Dec; 5(4):943-59. PubMed ID: 1822828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness analysis of hormone replacement therapy in the menopause.
    Cheung AP; Wren BG
    Med J Aust; 1992 Mar; 156(5):312-6. PubMed ID: 1588862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy.
    Tosteson AN; Rosenthal DI; Melton LJ; Weinstein MC
    Ann Intern Med; 1990 Oct; 113(8):594-603. PubMed ID: 2119161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.
    Whittington R; Faulds D
    Pharmacoeconomics; 1994 Jun; 5(6):513-54. PubMed ID: 10147266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy in a risk-benefit perspective.
    Daly E; Vessey MP; Barlow D; Gray A; McPherson K; Roche M
    Maturitas; 1996 Mar; 23(2):247-59. PubMed ID: 8735363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risks, benefits and costs of hormone replacement therapy in menopause].
    Gaspard U
    Rev Med Liege; 1998 May; 53(5):298-304. PubMed ID: 9689887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk.
    Armstrong K; Chen TM; Albert D; Randall TC; Schwartz JS
    Obstet Gynecol; 2001 Dec; 98(6):996-1003. PubMed ID: 11755544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture.
    Geelhoed E; Harris A; Prince R
    Aust J Public Health; 1994 Jun; 18(2):153-60. PubMed ID: 7948331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy to prevent disease and prolong life in postmenopausal women.
    Grady D; Rubin SM; Petitti DB; Fox CS; Black D; Ettinger B; Ernster VL; Cummings SR
    Ann Intern Med; 1992 Dec; 117(12):1016-37. PubMed ID: 1443971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.
    Mullins CD; Ohsfeldt RL
    J Manag Care Pharm; 2003; 9(2):150-8. PubMed ID: 14613344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
    Col NF; Pauker SG; Goldberg RJ; Eckman MH; Orr RK; Ross EM; Wong JB
    Arch Intern Med; 1999 Jul; 159(13):1458-66. PubMed ID: 10399897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and characteristics associated with use of hormone replacement therapy in Britain.
    Moorhead T; Hannaford P; Warskyj M
    Br J Obstet Gynaecol; 1997 Mar; 104(3):290-7. PubMed ID: 9091004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency.
    Whittington R; Faulds D
    Pharmacoeconomics; 1994 May; 5(5):419-45. PubMed ID: 10147233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study.
    Fleurence R; Torgerson DJ; Reid DM
    Osteoporos Int; 2002 Aug; 13(8):637-43. PubMed ID: 12181622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
    Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
    Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
    Anderson GL; Limacher M; Assaf AR; Bassford T; Beresford SA; Black H; Bonds D; Brunner R; Brzyski R; Caan B; Chlebowski R; Curb D; Gass M; Hays J; Heiss G; Hendrix S; Howard BV; Hsia J; Hubbell A; Jackson R; Johnson KC; Judd H; Kotchen JM; Kuller L; LaCroix AZ; Lane D; Langer RD; Lasser N; Lewis CE; Manson J; Margolis K; Ockene J; O'Sullivan MJ; Phillips L; Prentice RL; Ritenbaugh C; Robbins J; Rossouw JE; Sarto G; Stefanick ML; Van Horn L; Wactawski-Wende J; Wallace R; Wassertheil-Smoller S;
    JAMA; 2004 Apr; 291(14):1701-12. PubMed ID: 15082697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex hormones and cardiovascular risk.
    La Vecchia C
    Hum Reprod; 1992 Feb; 7(2):162-7. PubMed ID: 1577926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch women.
    Moerman CJ; Van Hout BA; Bonneux L; Witteman JC
    J Intern Med; 2000 Aug; 248(2):143-50. PubMed ID: 10947893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term hormone therapy for perimenopausal and postmenopausal women.
    Marjoribanks J; Farquhar C; Roberts H; Lethaby A
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004143. PubMed ID: 22786488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of hormone replacement.
    Weinstein MC; Tosteson AN
    Ann N Y Acad Sci; 1990; 592():162-72; discussion 185-92. PubMed ID: 2115756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.